| Literature DB >> 35205863 |
Muhammad Naeem1, Saba Manzoor2, Mashhud-Ul-Hasan Abid3, Muhammad Burhan Khan Tareen4, Mirza Asad5, Sajida Mushtaq6, Nazia Ehsan7, Dua Amna8, Baojun Xu9, Abu Hazafa5.
Abstract
With the increasing world population, demand for industrialization has also increased to fulfill humans' living standards. Fungi are considered a source of essential constituents to produce the biocatalytic enzymes, including amylases, proteases, lipases, and cellulases that contain broad-spectrum industrial and emerging applications. The present review discussed the origin, nature, mechanism of action, emerging aspects of genetic engineering for designing novel proteases, genome editing of fungal strains through CRISPR technology, present challenges and future recommendations of fungal proteases. The emerging evidence revealed that fungal proteases show a protective role to many environmental exposures and discovered that an imbalance of protease inhibitors and proteases in the epithelial barriers leads to the protection of chronic eosinophilic airway inflammation. Moreover, mitoproteases recently were found to execute intense proteolytic processes that are crucial for mitochondrial integrity and homeostasis function, including mitochondrial biogenesis, protein synthesis, and apoptosis. The emerging evidence revealed that CRISPR/Cas9 technology had been successfully developed in various filamentous fungi and higher fungi for editing of specific genes. In addition to medical importance, fungal proteases are extensively used in different industries such as foods to prepare butter, fruits, juices, and cheese, and to increase their shelf life. It is concluded that hydrolysis of proteins in industries is one of the most significant applications of fungal enzymes that led to massive usage of proteomics.Entities:
Keywords: catalytical properties; fungal enzymes; genetic engineering; mitoproteases; proteases; recent developments
Year: 2022 PMID: 35205863 PMCID: PMC8875690 DOI: 10.3390/jof8020109
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
The characteristics of different fungal enzymes.
| Enzyme Class | Type of Strain | Production Method | Mol. Weight (kDa) | Opt. pH | Opt. Temperature (℃) | Substrate | Inhibitors | Enzyme Activity (%) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Fungal amylase |
| SSF | 33 | 5 | 48 | Wheat straw, guayule bagasse | SDS | 88 | [ |
|
| SmF | 28 | 4.5 | 30 | Pomegranate peel, wheat bran | Ebselen | 90 | [ | |
|
| SSF | 70 | 5 | 45 | Starch, amylose | Mercury | 80–84 | [ | |
|
| SSF | 115 | 5 | 75 | Cowpeas, chickpeas | 88 | [ | ||
| SSF | 38 | 4 | 30 | Kidney beans, lupine | EDTA | 84–86 | [ | ||
|
| SSF | 102 | 8 | 30 | Groundnut oil, sesame oil | Copper | 85 | [ | |
|
| SSF | 110 | 3 | 32 | Pearl millet | Mercury | 88–90 | [ | |
|
| SSF | 25 | 6 | 28 | Cowpeas, chickpeas | Lead | 78 | [ | |
| Fungal cellulase |
| SSF | 55 | 7 | 52 | CMC | Mercury | 86–88 | [ |
| SmF | 30 | 4 | 58 | SKT | EDTA | 80 | [ | ||
|
| SSF | 70 | 3.5 | 32 | RW, bread | Mercury | 90 | [ | |
|
| SSF | 40 | 5 | 70 | Sugarcane bagasse | EDTA | 85 | [ | |
|
| SSF | 29 | 4 | 52 | Sugar cane, CMC | Zinc | 95 | [ | |
|
| SmF | 52 | 3.5 | 13 | Cowpeas, chickpeas | Mercury | 78 | [ | |
| Fungal lipase |
| SSF | 30 | 3 | 40–48 | Coir waste, RH | Zinc | 88 | [ |
|
| SmF | 35 | 3.5 | 48 | MOC | α-Glucosidase | 85 | [ | |
|
| SmF | 93 | 7 | 60 | EMO | Lipstatin | 90 | [ | |
|
| SSF | 5 | 4.5 | 55 | GOC, agrowastes | Ebelactone | 92 | [ | |
|
| SmF | 9 | 4.6 | 25 | SFO, casein | Caulerpenyne | 88 | [ | |
| SmF | 7 | 4.2 | 28 | Kidney beans, lupine | Percyquinin | 66 | [ | ||
| Fungal protease | SSF | 38 | 8 | 56 | Glucose, peptone | NBS | 88 | [ | |
|
| SSF | 47 | 7 | 45 | Cowpeas, chickpeas | EDTA | 88 | [ | |
|
| SSF | 40 | 8 | 31 | PL, casein | DTT | 90 | [ | |
|
| SmF | 55 | 5 | 32 | WBW | DTT | 75 | [ | |
| SSF | 35 | 7 | 28 | Kidney beans, lupine | EDTA | 88 | [ | ||
|
| SmF | 48 | 7–8 | 29 | Soya bean meal | IAA | 85 | [ | |
|
| SSF | 45 | 7 | 19 | Glutamine | PMSF | 80–82 | [ |
Note: SDS = Sodium Dodecyl Sulfate, EDTA = Ethylenediaminetetraacetic acid, DTT = Dithiothreitol, NBS = N-bromosuccinimide, PMSF = Phenylmethylsulphonylfluoride, IAA = Indole Acetic Acid, SSF = Solid-state fermentation, SmF = submerged fermentation, RH = Rice Husk, MOC = Mustard Oil Cake, GOC = Gingili Oil Cake, EMO = Edible Oil Mill, SFO = Sunflower Oil, PL = Pig Hung, CMC = Carboxy Methyl Cellulose, SCT = Silk Cotton Tree, RW = Rose Wood, and WBW = White Bread Waste.
The coproduction of fungal enzymes from different strains of fungus based on temperature.
| Fungal Strain | Nature | Genus | Opt. Temperature (°C) | Fungal Amylase | Fungal Cellulase | Fungal Lipase | Fungal Protease | Application | Reference |
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| 40–50 | √ | ✕ | √ | √ | Wastewater and pharmaceuticals waste treatment | [ |
|
|
|
| 45–50 | ✕ | √ | ✕ | √ | Biomass degradation | [ |
|
|
|
| 45–50 | ✕ | √ | ✕ | √ | Textile industries and bioremediation | [ |
|
|
|
| 46–55 | ✕ | ✕ | √ | √ | Wastewater treatment | [ |
|
|
|
| 20–30 | ✕ | √ | ✕ | √ | As a model organism in an analysis of genetic recombination | [ |
|
|
|
| 20–30 | √ | ✕ | ✕ | √ | Food industries | [ |
|
|
|
| 25–30 | √ | √ | ✕ | √ | Textile, detergent, and paper industries | [ |
|
|
|
| 5–10 | √ | ✕ | √ | √ | Food industries | [ |
Note: The tick (√) represents ‘produce’, and cross (✕) represents ‘not produce’.
Figure 1The representation of (a) structure and (b) topology of proteases. TM: Transmembrane domain, IBM: Inhibitor of apoptosis (IAP)-binding motif, MTS: Mitochondrial targeting sequencing, IMS: Intermembrane space, CC: Coiled-coil, AAA: Triple-A domain, M41: Protease metal-binding proteolytic domain, S1 protease: Trypsin-like protease domain. This figure is reproduced from Martinelli and Rugarli [94] after permission from Elsevier (License No. 5197711293142).
The representation of novel fungal protease enzymes isolated from different sources.
| Enzyme Isolated | Enzyme Class | Active Site Residue (s) | Isolated Source | Reference |
|---|---|---|---|---|
| Clostripain, Streptopain | Cysteine proteases | Cysteine and histidine residues | [ | |
| Pepsins, proteases, rennet like proteases | Aspartic endoproteases | Two aspartate residues | [ | |
| Chymotrypsins, subtilisins | Serine proteases | Serine residues |
| [ |
| Collagenases, elastase | Metalloendoproteases | Metal ions | [ | |
| Eqolisin protease | Glutamic proteases | Glutamate residues | [ | |
| Pepsins (A1), retropepsin (A2) | Acidic proteases | - | [ | |
| Subtilisin, carlsberg | Alkaline proteases | - | [ | |
| Neutrase, thermolysin | Neutral proteases | - | [ |
Figure 2The representation of fungal protease mechanisms of (a) serine proteases (b) aspartyl proteases, (c) metalloproteases, and (d) cysteine proteases. It was reported that the eponymous residue is commonly formed as a pair with a proton withdrawing group in the active sites of cysteine and serine proteases to promote a nucleophilic attack on the peptide bond. In contrast, metalloproteases and aspartyl proteases activate water molecules as nucleophiles. Overall, it was observed that the process of peptide bond scission is the same for all classes of proteases. This figure is reproduced from Erez et al. [135] after permission from Springer Nature (License No. 5223461087907).
Figure 3The representation of a comparison of the two hydrolytic mechanisms used for proteolysis. This figure is reproduced from Shafee [136] (Attribution NonCommercial 2.0 UK: England & Wales, CC BY-NY 2.0 UK).
The applications and efficiencies of different fungal enzymes isolated from fungal strains recently modified through CRISPR technology.
| Fungal Strain | Isolated Proteases | CRISPR System | Selective Marker | Promoter for sgRNA | Promoter for Cas9 | Delivery Method | Editing Method | Application | Efficiency (%) | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
|
| Aspartic acid protease | Cas-9 |
| U6 |
| PMT | NHEJ | Genetic engineering, food industries | 10–30 | [ |
|
| Alkaline protease | Cas-9 |
| U6 |
| AMT | HDR | pharmaceuticals biomass/waste treatment | 20–95 | [ |
|
| Serine alkaline protease | Cas-9 |
| U6 |
| AMT | NHEJ | Wastewater and pharmaceuticals waste treatment | 44–90 | [ |
|
| Serine alkaline protease | Cas-9 | 5-FOA/blpR | U6 |
| AMT | NHEJ | Pharmacecurials | 82–89 | [ |
|
| Acid proteases | Cas-9 |
| U6 |
| AMT | HDR | Food indsuries, pests conrol | 2–12 | [ |
|
| Metalloproteases | Cas-9 |
| U6 |
| PMT | NHEJ | Biofuels, pharmacuetcals | 50–90 | [ |
|
| Serine proteases | Cas-9 |
| SNR52 |
| AMT | HDR | Genetic recombination | 60–80 | [ |
|
| Metalloproteases | Cas-9 |
| T7 |
| PMT | NHEJ | Medicine | 28–33 | [ |
Note: NHEJ = Non-homologous end joining, HDR = High-fidelity homology-directed repair, Cas = CRISPR-associated genes, gRNA = Guide RNA, sgRNA = Single guide RNA, AMT = Agrobacterium mediated transformation, and PMT = Protoplast transformation.
Figure 4The mechanism of action of mitoprotease peptidases. Mitoproteases are the diverse group of enzymes that transport the biologically active proteins from cytosol to the inner mitochondrion to carry out the correct signals necessary for cellular processes [182]. Mitochondrial processing peptidase (MPP) is the part of the mitochondrial matrix that comprises two subunits such as PMPCA and PMPCB (protease mitochondrial processing peptidase subunit a and b) [183]. Mitochondrial intermediate peptidase (MIP) promotes the cleavage of octapeptide and X-Pro aminopeptidase 3 (XPNPEP3) that removed the amino acids from the amino-terminal of the MPP. Some proteins also pass through further photolytic cleavage via IMMP1L and IMMP2L. IMMPs attack the carboxy-terminal sequence (CTS) to promote cellular assembly [184]. Met aminopeptidase 1D (METAP1D) attacks on amino terminals of the initial Met of some of the polypeptides in order to get functionally active proteins [180]. This figure is reproduced from Quiros et al. [181] after permission from Springer Nature (License No. 5197691283486).
Figure 5The representative structure of (a) fold of mature cathepsin L and (b) role of cathepsins in regulating inflammation in atherosclerosis. Cathepsins are involved in the regulation of inflammation in atherosclerosis by clearing the apoptotic cell [187]. Cathepsin function in atherosclerosis is catalyzed by suppressing the oily foam formation that leads to atherosclerosis in arteries due to excess cholesterol that increases the chances of reactive oxygen species and hence strong activity by clearance of the apoptotic cell. Cathepsins move into the cytosol by promoting apoptosis by degrading excess high-density lipoproteins (HDL) by processing the IL-1β [188,189]. Lysosomes bind to Low-density lipoprotein receptors (LDLR), causing them to degrade fatty acids and lipids through acid hydrolases. Impairment in cathepsin’s catalytic functioning leads to the deposition of excess cholesterol that causes stress and free radicals due to reactive oxygen species [185]. tBID: Truncated BID, LMP: Lysosomal membrane permeabilization, TLR: Toll-like receptor, ABCA1: ATP-binding cassette transporter, ABCG1: ATP-binding cassette sub-family G member 1, BID: BH3-interacting domain death. This figure is reproduced from Weiss-Sadan et al. [185] (Attribution 4.0 International, CC BY 4.0).
Figure 6The mechanism of action of proteases to inhibit the allergen and other microbe attacks. Proteases are released in response to allergens due to a microbial attack that causes severe damage to epithelial cells by disrupting the junctional proteins [192]. Allergen proteases bind to protease-activated receptor 2 (PAR2) by cleaving the fibrinogen into the fibrin cleavage products (FCPs) that activate the toll-like receptor 4 (TLR4) and ILC2s. These ILC2s lead to activation of NF-kB and excess production of reactive oxygen species (ROS). It activates epithelial cells to release the pro-Th2 cell chemokines and cytokines that activated the instruct immature dendritic cells (iDCs). P-glycoproteins (P-gp) helps in removing the protease inhibitors in epithelial cells that cause the suppression of allergen proteases [190,193]. This figure is reproduced from Wu et al. [190] (Attribution 4.0 International, CC BY 4.0).
Figure 7The application of fungal proteases in the food industry.
Fungal protease inhibitors for biomedical applications.
| Type of Fungal Protease Inhibitors | Proteases Inhibited | Family | Activity | Inhibitory Mechanism | Application | Reference |
|---|---|---|---|---|---|---|
| Survivin (Cysteine inhibitor) | Caspases- specific cysteine proteases | C14 | Antifungal | Tight binding | Role as a mitotic regulator of cell division and as an inhibitor of caspase activation in the process of apoptosis. | [ |
| Diosgenin (Metalloprotease inhibitor) | Metalloproteases | M15 | Antifungal | Tight binding | These inhibit the secreted metallopeptidase relevant in brain invasion by cryptococcal cells, causing meningoencephalitis. | [ |
| Serpin (Serine inhibitor) | Serine Proteases | C1 and C14 | Antifungal | Trapping traps the serine protease in a covalent complex | Fungal serpins as a therapeutic benefit toward several inflammation-related complications. | [ |
| Saccharo (Pepsin, aspartic acid inhibitor) (IA3) | Aspartic acid proteases | C1 | Antifungal | Tight binding | Role as an inhibitor in the process of apoptosis and cancer. | [ |
| Streptomyces (Metallopeptidase inhibitor) | Metalloproteases | C14 | Antifungal | Tight binding | Role as an inhibitor in tumor invasion and metastasis (the most validated target for cancer). | [ |
| RflP-1 (Rhamnus frangula inhibitor proteases) | Serine protease | C14 | Antifungal | Trapping | Role in free radical scavenging activities. | [ |
Figure 8Mechanism of action of fungal protease inhibitors. (a) Trapping reaction-irreversible interaction and (b) Tight binding interaction-reversible interaction. This figure is reproduced from Rudzinska et al. [216] (Attribution-NonCommercial 3.0 Unported, CC BY-NY 3.0).
Representation of protease inhibitors under clinical trials with the mechanism of action and therapeutic uses.
| Name of Inhibitor | Targeted Enzyme | Target Disease | Clinical Trials Stage | Reference |
|---|---|---|---|---|
| RO033-4649 | Therapeutic agents have reduced the rate of mortality and are helpful for treatment | AIDS | Under the clinical phase I | [ |
| VX-950 | Become the most common cause of liver cirrhosis | HCV | Under the clinical trial phase II | [ |
| COL-3 | Therapeutic agents to control the different mutations in colon cancer | Colon cancer | Entered the phase II stage | [ |
| AG3340 | Therapeutic agents to control the different mutations in lung cancer | Lung cancer | Entered the phase II stage | [ |
| TMC-114 | Therapeutic agents have reduced the rate of mortality and are helpful for the treatment | AIDS | Under clinical phase III | [ |
| Indinavir | These inhibitors bind to the HIV and inhibit the viral replication | HIV | FDA has approved this inhibitor | [ |
| Ritonavir | These inhibitors bind to the HIV and inhibit the viral replication | HIV | FDA has approved this inhibitor | [ |
| GP205 | GP205 inhibitor showed the biological activities in targeting the HCV virus, and ultimately, this novel inhibitor could be for possible treatment for Hepatitis C virus | HCV | GP205 inhibitor showed the biological activities in targeting the HCV virus, and ultimately, this novel inhibitor could be for possible treatment for Hepatitis C virus | [ |
| Quercetin 3-β-d-glucoside and helichrysetin | The biochemical analysis of these compounds showed biological activities in the suppression of the MERS-COV 3Cl protease | Coronaviruses | These chemical compounds could be used as a possible treatment in targeting the coronaviruses | [ |
| Mpro inhibitors | These inhibitors play a role in processing the replicase during the post-translational process’s viruses of the | Coronaviruses | These proteases can be used for antiviral drug and discovery | [ |
| PLpro inhibitors | These inhibitors play a vital role in transcription by the processing of the two polyproteins, pp1a and pp1ab | Coronaviruses | These proteases also can be used for the discovery of novel protease inhibitors | [ |
| NP-delivery systems-based carfilzomib and bortezomib | This nanotechnology-based approach could help reduce the side effects of drugs | These protease inhibitors can be designed with combinations with gold, PEGlycated, silica, liposomes and demonstrate the high efficacy rate | Future discovery of novel inhibitors based on modified NP-systems protecting the normal tissues and improving the quality of patients | [ |